Diabetes Drug Protects Against Skin Cancer, New Research Says
Diabetes Drug Protects Against Skin Cancer, New Research Says
By Dennis Thompson, HealthDay Reporter
TUESDAY, Jan. 14, 2025 -- A popular diabetes drug can provide protection against skin cancers, a new study says.
In a recent study published in the Journal of Drugs in Dermatology, researchers found that metformin significantly reduces the risk of developing basal or squamous cell cancer, the two most common skin cancers.
People taking metformin had a significantly lower risk of basal cell cancer and a significantly lower risk of squamous cell cancer, results show.
"This study strengthens the evidence supporting metformin's potential as a protective agent against non-melanoma skin cancer," concluded the research team led by senior researcher Dr. Tiffany Libby, an assistant professor of dermatology at Brown University.
Metformin is now the most widely prescribed pill for type 2 diabetes, researchers said in background notes.
Previous studies have suggested that metformin might lower a person's risk of skin cancer.
According to the American Cancer Society, about 5.4 million basal and squamous cell skin cancers are diagnosed each year in the U.S., and eight out of ten are basal cell cancers.
Deaths from these skin cancers are not common. Only about 2,000 to 8,000 people a year die from skin cancers that aren't melanoma, which is much more dangerous, the ACS says.
For this study, researchers compared a healthy control group against more than 8,000 people diagnosed with basal cell cancer and more than 4,100 patients with squamous cell cancer.
Researchers said each person with skin cancer was matched with four healthy people who shared their age, race, ethnicity, and sex. The patient data came from a diverse health database maintained by the National Institutes of Health.
Results showed that metformin users did indeed have a lower risk of skin cancers, significantly after researchers adjusted for other medications that can increase the risk of skin cancer.
However, the drug did not protect Black patients against squamous cell cancers, researchers found.
"This discrepancy could stem from the fact that SCC in these patients often develops in unprotected areas and is strongly linked to chronic scarring and inflammation, factors that may not be influenced by metformin use," "the research team wrote.
Researchers said metformin might protect against skin cancer by regulating mechanisms of blood cells' access to energy and nutrients or blocking their ability to grow and proliferate.
Metformin also promotes the death of unhealthy cells, enhances the body's immune response to cancer cells, reduces inflammation, and inhibits the growth of new blood vessels to skin tumors.
"In conclusion, our results suggest that further research may be warranted to consider metformin as a chemopreventive agent," the researchers concluded.
Comments
Post a Comment